Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RHOH
REST API REST API
Homo sapiens
RHOH is differentially expressed in 233 experiments: 87 organism parts: thymus, tonsil, ... (85 more);, 223 disease states: normal, acute myeloid leukemia, ... (221 more);, 92 cell types 389 cell lines 40 compound treatments and 69 other conditions.
Synonyms RhoH, ARHH, TTF
Orthologs E1BVI6_CHICK (Gallus gallus)   rhoh (Danio rerio)   F1N7X6_BOVIN (Bos taurus)   Rhoh (Mus musculus)   Rhoh (Rattus norvegicus)   NP_001120435.1 (Xenopus laevis)   RHOH (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, GTPase activity, protein binding, regulation of transcription, DNA-dependent, cytoplasm, intracellular, membrane, GTP catabolic process, GTP binding, small GTPase mediated signal transduction, regulation of small GTPase mediated signal transduction, nucleotide binding, signal transduction, protein transport, mitochondrion, immunological synapse, negative regulation of I-kappaB kinase/NF-kappaB cascade, mast cell activation, Rho GTPase binding, negative regulation of phosphorylation, kinase inhibitor activity, GTPase inhibitor activity, T cell differentiation
InterPro Term MIRO-like, Small_GTPase, Small_GTP-bd_dom, Small_GTPase_ARF/SAR, Small_GTPase_Ras, Small_GTPase_Rho, Small_GTPase_Rab_type
UniProt Accession Q15669, D6RA52, D6RG23, Q6ICP4
Search EB-eye ENSG00000168421
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-1880, E-GEOD-22152, E-GEOD-22639, ... (23 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
Jurkat
2
E-GEOD-1880, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
HL-60
1
2
E-GEOD-24147, E-MTAB-37, E-GEOD-5258
K562
1
2
E-GEOD-24147, E-MTAB-37, E-GEOD-96
HCC1937
1
E-MTAB-37
383 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-750, E-MEXP-66, E-GEOD-13909, E-GEOD-20677, ... (47 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-TABM-145, E-MTAB-25
monocyte
1
3
E-GEOD-11755, E-MEXP-583, E-GEOD-8286, E-MEXP-2019
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
1
2
E-MEXP-1600, E-AFMX-5, E-TABM-145
central memory T cell
1
E-GEOD-3982
adult native RPE from 89 y.o. donor
1
E-GEOD-18811
86 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-TABM-15, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
3
E-GEOD-96, E-MTAB-62, E-MTAB-37, E-MEXP-2034
chronic myelogenous leukemia
1
3
E-MTAB-37, E-MTAB-62, E-GEOD-5550, E-GEOD-96
retinoblastoma
2
E-GEOD-96, E-MTAB-37
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
adenocarcinoma
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-37, E-MTAB-62
217 more value(s).


Compound treatment

studied in E-GEOD-7400, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (27 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-GEOD-3720, E-TABM-868
resveratrol
1
E-TABM-782
vanadium pentoxide
1
E-GEOD-5339
placebo
1
E-MEXP-1335
BCR/ABL1
1
E-GEOD-15811
ZMYM2/FGFR1
1
E-GEOD-15811
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-2666, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-21138, E-GEOD-19665 ... (5 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-GEOD-17385, E-GEOD-361

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-TABM-321, E-TABM-868, E-TABM-601, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-22278, E-GEOD-10315, E-MEXP-2146 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-MEXP-2069, E-TABM-666, ... (23 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-360 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-22056

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22229, E-GEOD-4525, E-GEOD-19703, E-GEOD-22309, E-GEOD-1657, ... (7 experiments)

Population
studied in E-MTAB-197, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19246

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-2466

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.305 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM